Commentary

TBI and growth hormone


 

References

In response to “Traumatic brain injury: Pharmacotherapy options for cognitive deficits” (Med/Psych Update, Current Psychiatry, February 2011, p. 21-37), traumatic brain injury (TBI) has been recognized as a risk factor for cognitive impairment, but TBI also has been shown to be a risk factor for hypopituitarism, presenting most frequently with growth hormone deficiency (GHD). GHD is associated not only with changes in body composition but also with impaired quality of life, cognitive dysfunctions, and psychiatric sequelae, usually classified as “depression.”

In a case study we evaluated the impact of GH therapy on the mental status of TBI patients.1 Psychiatric and cognitive functions were tested in 6 GHD patients at baseline (minimum 3 years after TBI) and reassessed after 6 months of GH therapy and 12 months after discontinuing GH therapy. Psychiatric and cognitive examinations included semi-structured interviews and 3 instruments: Symptom Checklist-90-Revised, Zung Depression Inventory, and a standard composite neuropsychological battery.

Our results showed that 6 months of GH therapy in GHD TBI patients improved cognitive abilities (particularly verbal and nonverbal memory) and significantly improved psychiatric functioning. Depression severity decreased, as did intensity of interpersonal sensitivity, hostility, paranoid ideation, anxiety, and psychoticism. Somatization, obsessive-compulsive symptoms, and phobic anxiety decreased in all but 1 patient. In 3 GHD patients who stopped GH therapy for 12 months, we observed worsening verbal and nonverbal memory, interpersonal sensitivity, anxiety, and paranoid ideation. Thus, GHD might be associated with affective and cognitive symptoms in TBI patients and GH replacement therapy could be beneficial. Screening for pituitary dysfunction in TBI patients is strongly recommended, particularly in presence of cognitive and affective symptoms.

Nadja Maric, MD, PhD
Associate Professor
Head of Department for Research and Early
Interventions in Psychiatry
Clinic for Psychiatry, Clinical Centre of Serbia
University of Belgrade School of Medicine
Belgrade, Serbia

Recommended Reading

Creative-Expression Programs Benefit Patients With Dementia
MDedge Psychiatry
Amyloid Burden May Be Tied to Cognitive Status in Parkinson’s
MDedge Psychiatry
Despite Setbacks, Promising Alzheimer's Treatments Still in Pipeline
MDedge Psychiatry
Meta-Analysis Questions Memantine Effectiveness for Mild Alzheimer’s
MDedge Psychiatry
Hypoglycemia in Older Diabetics Could Point to Cognitive Impairment
MDedge Psychiatry
Apathy Limits Executive Functioning in Nondemented Parkinson’s Patients
MDedge Psychiatry
Treatments Few for Alzheimer's, Parkinson's, Lewy Body Dementia
MDedge Psychiatry
P300 Evoked Potential May Identify Early Brain Deterioration
MDedge Psychiatry
Neuropsychiatric Symptoms Predict Progression From Mild Cognitive Impairment to Dementia
MDedge Psychiatry
New Alzheimer's Criteria Name Three Stages
MDedge Psychiatry